Media headlines about Mesa Laboratories (NASDAQ:MLAB) have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. Accern scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Mesa Laboratories earned a coverage optimism score of 0.07 on Accern’s scale. Accern also gave headlines about the medical instruments supplier an impact score of 46.8465958519509 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Shares of Mesa Laboratories (NASDAQ MLAB) traded up 1.49% during trading on Tuesday, hitting $139.50. 2,868 shares of the company’s stock were exchanged. Mesa Laboratories has a 12-month low of $109.14 and a 12-month high of $169.80. The company has a market cap of $524.24 million, a P/E ratio of 50.14 and a beta of 0.47. The company has a 50-day moving average of $136.63 and a 200-day moving average of $137.77.
Mesa Laboratories (NASDAQ:MLAB) last issued its earnings results on Monday, July 31st. The medical instruments supplier reported $0.39 EPS for the quarter, missing the Zacks’ consensus estimate of $0.56 by ($0.17). The business had revenue of $22.67 million during the quarter, compared to analyst estimates of $22.90 million. Mesa Laboratories had a net margin of 11.31% and a return on equity of 16.58%. On average, equities analysts expect that Mesa Laboratories will post $2.72 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Thursday, August 31st will be given a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a dividend yield of 0.47%. The ex-dividend date of this dividend is Tuesday, August 29th. Mesa Laboratories’s dividend payout ratio (DPR) is 22.94%.
A number of brokerages have commented on MLAB. BidaskClub cut shares of Mesa Laboratories from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 12th. Zacks Investment Research cut shares of Mesa Laboratories from a “buy” rating to a “strong sell” rating in a research note on Thursday, August 3rd. Finally, TheStreet cut shares of Mesa Laboratories from a “b” rating to a “c+” rating in a research note on Monday, July 31st.
In other news, Director H Stuart Campbell sold 1,000 shares of the stock in a transaction dated Monday, August 21st. The shares were sold at an average price of $130.16, for a total value of $130,160.00. Following the completion of the sale, the director now directly owns 42,366 shares in the company, valued at $5,514,358.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Robert V. Dwyer sold 11,150 shares of the stock in a transaction dated Friday, June 16th. The shares were sold at an average price of $139.46, for a total transaction of $1,554,979.00. Following the completion of the sale, the director now owns 80,671 shares of the company’s stock, valued at $11,250,377.66. The disclosure for this sale can be found here. Insiders sold 19,760 shares of company stock valued at $2,731,788 over the last quarter. Company insiders own 17.00% of the company’s stock.
Mesa Laboratories Company Profile
Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.
Receive News & Ratings for Mesa Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.